A majority of these studies are looking to see how the investigational medication works for a patient experiencing a 4wk-36month MDE and who has not already demonstrated an inadequate response to multiple depression medications for the same episode
An adjunctive trial typically is looking to see how the investigational medication works in patients who are already on an antidepressant for their 6wk-60month MDE and who have experienced less than 50% improvement in symptoms. Depending on the study, participants will either maintain their ADT or discontinue and change to another marketed ADT to take with the investigational medication
GAD trials are looking to see how an investigational medication helps symptoms of GAD. Most studies do not allow concurrent treatment with another anxiolytic and do not allow comorbid depression or treatment for depression.
Our current SAD trial includes screening, a treatment visit for qualified participants, and a followup phone call. The treatment visit consists of a single dosing of the study medication (or matching placebo) and followup questions/scales to evaluate effect.
Qualifying participants will receive a subcutaneous dose at their second visit including an 8 hour in-office observation, followed by weekly visits for a month. This is a one-dose only study which may show promise in rapidly decreasing depressive symptoms over a longer time frame.
This study looks at the effectiveness of a daily dose of study medication versus placebo over the treatment period in which participants keep a diary of their binge episodes throughout.
This study will be looking at the effect of a psychedelic drug versus placebo in reducing PTSD symptoms. Stay tuned.
This study will be looking at the effects of a single dose of study medication to treat an acute migraine attack. Stay tuned!